Amplia Therapeutics Ltd (ASX:ATX) has received a Research and Development Tax Incentive Refund of $1,140,352.91 for the 2020/2021 financial year.
The Australian Government’s Research and Development Tax Incentive Refund provides eligible companies with cash refunds for 43.5% of eligible expenditure on research and development activities.
This refund recognises research and development expenses associated with ATX’s FAK (focal adhesion kinase) inhibitors, AMP945 and AMP886.
The company is developing two potent inhibitors of focal adhesion kinase (FAK) - a protein involved in cell adhesion and spreading processes - which dictate how cells stick to each other and move around.
The importance of FAK
FAK is becoming more and more important in the field of cancer immunology.
Amplia’s development focus is in pancreatic and ovarian cancer.
FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF)
Amplia’s R&D activities primarily relate to its Phase 1 clinical trial of AMP945 in healthy volunteers and associated preparatory works.
The trial was completed during the first half of 2021 and leads into the company’s planned Phase 2 clinical trial in pancreatic cancer patients.
